A phase I/II study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: A gynecologic oncology group study

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 78-84

  Walker, Joan L ^a   Morrison, Astrid ^b   DiSilvestro, Paul ^c   von Gruenigen, Vivian E ^d  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b St Anthony Hospital Oklahoma City   (United States)

^c WOMEN AND INFANTS HOSPITAL   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Cervical carcinoma; Concomitant paclitaxel and cisplatin chemotherapy; Extended field radiation therapy; GOG; Metastatic to the para aortic lymph nodes

Indexed keywords

CISPLATIN; PACLITAXEL;

ALLERGY; ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; EYE TOXICITY; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG EMBOLISM; LUNG TOXICITY; LYMPH NODE METASTASIS; LYMPHATIC SYSTEM DISEASE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PAIN; PERCEPTION DEAFNESS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE; SEXUAL DYSFUNCTION; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINARY TRACT INFECTION; UTERINE CERVIX CARCINOMA; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PACLITAXEL; UTERINE CERVICAL NEOPLASMS;

EID: 57649102930     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.09.035     Document Type: Article

References (16)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J. Clin. 57 (2007) 43-66
2. Monk B.J., and Tewari K.S.T. Invasive cervical cancer. In: DiSaia P.J., and Creasman W.T. (Eds). Clinical Gynecologic Oncology. 7th (2007), Elsevier, Philadelphia PA 55-124
3. Whitney C.W., Sause W.T., Bonomi P., and Liao S. A randomized comparison of hydroxyurea versus 5-FU infusion and bolus cisplatin as an adjunct to radiation therapy in patients with stages II-B, III and IV-A carcinoma of the cervix and negative para-aortic nodes. J. Clin. Oncol. 17 (1999) 1339-1348
4. Morris M., Eifel P.J., Lu J., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Eng. J. Med. 340 (1999) 1137-1143
5. Rose P.G., Bundy B.N., Watkins E.B., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Eng. J. Med. 340 (1999) 1144-1153
6. Peters W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 18 (2000) 1606-1613
7. Keys H.M., Bundy B.N., Stehman F.B., et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Eng. J. Med. 340 (1999) 1154-1161
8. National Cancer Institute Clinical Announcement. Concurrent Chemoradiation for Cervical Cancer. February, 1999 (http://www.cancer.gov/newscenter/cervicalcancer) (Accessed 11/03/08).
9. Berman M.L., Keys H., Creasman W., et al. Survival and patterns of recurrence in cervical carcinoma metastatic to periaortic lymph nodes (a gynecologic oncology group study). Gynecol. Oncol. 19 (1984) 8-16
10. Varia M.A., Bundy B.N., Deppe G., Mannel R., Averette H.E., Rose P.G., and Connelley P. Cervical carcinoma metastatic to para-aortic nodes: extended filed radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. Int. J. Rad. Oncol. Biol. Phys. 42 5 (1998) 1015-1023
11. McGuire W.P., Blessing J.A., Moore D., Lenta A.A., and Photopulos G. Paclitaxel has moderate activity in squamous cervix cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 14 (1996) 792-795
12. Moore D.H., Blessing J.A., McQuellon R.P., et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 (2004) 3113-3119
13. Choy H., and Browne M.J. Paclitaxel as a radiation sensitizer in non-small cell lung cancer. Sem in Oncol. S22 (1995) 70-74
14. Havemann K., Wolf M., Goerg C., Faora C., Pfab R., and Diergarten K. Paclitaxel and simultaneous radiation in the treatment of stage III A-B non-small cell lung cancer. Sem in Oncol. S22 (1995) 19-22
15. Chen M.D., Paley P.J., Potish R.A., et al. Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol. Oncol. 67 (1997) 131-136
16. DiSilvestro P.A., Walker J.L., Morrison A., Rose P.G., Homesley H., and Warshal D. Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: a phase I/II study of the Gynecologic Oncology Group. Gynecol. Oncol. 103 3 (2006) 1038-1042